CClinicalTrials.gg
CompletedNCT06719726Updated Jul 16, 2025

PECS I Block vs. Local Infiltration in Breast Augmentation Pain Management

An interventional study of PECS I Block and Local Anesthetic Infiltration in Breast Augmentation, Pain Management in Postoperative Care and Pain Management After Surgery, sponsored by Yeditepe University Hospital. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Yeditepe University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 59 Years
Sex
Female
01

Study summary

This study aimed to compare the effectiveness of preoperative PECS I block and intraoperative local anesthetic infiltration in managing postoperative pain following breast augmentation surgery. The primary focus was to evaluate their impact on postoperative pain levels, perioperative remifentanil and postoperative opioid consumption and opioid-related side effects during the early recovery period.

Read the detailed description

Breast augmentation is one of the most performed procedures in aesthetic surgery worldwide.These techniques, which involve muscle dissection and manipulation, tend to be more painful compared to subglandular and subfascial placements. Thus, managing postoperative pain effectively becomes a critical aspect of patient recovery and satisfaction.

To address postoperative pain in breast augmentation, various techniques, including regional anesthesia such as pectoral nerve blocks, local anesthetic infiltration, and pocket irrigation, are employed.

This study aimed to compare the effectiveness of preoperative PECS I block and intraoperative local anesthetic infiltration in managing postoperative pain following breast augmentation surgery. The primary focus was to evaluate their impact on postoperative pain levels, perioperative remifentanil and postoperative opioid consumption and opioid-related side effects during the early recovery period.

This prospective, double-blind, split-body design study was conducted at Yeditepe University Faculty of Medicine, Plastic, Reconstructive, and Aesthetic Surgery Department, in collaboration with the Anesthesiology and Reanimation Department.

The anesthesia induction and PECS I blocks for the right breasts were performed by the same anesthesiologist in all patients (O.K.). Breast augmentation surgeries and local anesthetic infiltrations for the left breasts were performed by the same plastic surgeon (M.E.). Postoperative pain assessments were conducted by a different anesthesiologist who was blinded to the study design.

Postoperative pain was assessed using the Numeric Rating Scale (NRS), ranging from "0 = no pain" to "10 = unbearable pain." Pain assessments were performed every 30 minutes for the first 2 hours, every 2 hours between 2 and 6 hours, and at the 24ᵗʰ hour postoperatively.

02

Conditions studied

  • Breast Augmentation
  • Pain Management in Postoperative Care
  • Pain Management After Surgery
  • Pain Management

Browse trials for

Keywords

  • breast augmentation
  • local infiltration
  • PECS 1 block
  • pectoral nerve block
  • postoperative pain management
03

In context

Agnosia

1,190 studies on the registry are indexed under Agnosia; 508 are open to participants now.

This study's enrollment of 20 is below the median of 78 across 1,024 interventional studies indexed under Agnosia.

Browse Agnosia studies →

Lead sponsor

Yeditepe University Hospital is the lead sponsor of 14 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Female participants aged 18 to 59 years.
  • ASA (American Society of Anesthesiologists) physical status I or II.
  • Scheduled for primary breast augmentation surgery using a dual-plane or submuscular approach.
  • Planned to receive silicone implants of identical volume and shape for both breasts.
  • Able to provide written informed consent.
  • Willing and able to comply with study procedures and follow-up assessments.

Exclusion criteria

Exclusion Criteria:

  • Planned subglandular or subfascial breast augmentation.
  • Undergoing revision breast surgery.
  • History of breast disease, previous breast or axillary surgery, or breast cancer.
  • Preoperative breast pain or chronic pain syndromes (e.g., fibromyalgia, chronic headaches, back pain, complex regional pain syndrome, neuropathic pain, osteoarthritis, or radicular pain).
  • BIRADS score > 3 based on imaging (ultrasound/mammography) within the past year.
  • Allergy to medications used in the study (e.g., bupivacaine, propofol, fentanyl, sevoflurane, cefazolin, paracetamol, ondansetron, tramadol, or morphine HCl).
  • Coagulopathy or bleeding disorders.
  • Pregnant or at risk of pregnancy.
  • Inability to provide informed consent or communication difficulties.
  • Significant medical conditions that may interfere with the study outcomes.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    PECS I Block Intervention Arm

    This arm involves the application of a preoperative PECS I block with 10 mL of 0.5% bupivacaine under ultrasound guidance. The intervention targets the right breast, aiming to evaluate its effectiveness in managing postoperative pain compared to local anesthetic infiltration.

    Procedure: PECS I Block

  • Experimental
    Local Anesthetic Infiltration Intervention Arm

    This arm involves the administration of intraoperative local anesthetic infiltration using 10 mL of 0.5% bupivacaine under direct visualization. The intervention targets the left breast, aiming to compare its effectiveness in managing postoperative pain against the PECS I block.

    Procedure: Local Anesthetic Infiltration

Interventions

  • ProcedurePECS I Block

    The PECS I block is a regional anesthesia technique performed preoperatively under ultrasound guidance. It involves the injection of 10 mL of 0.5% bupivacaine between the pectoralis major and pectoralis minor muscles to block the medial and lateral pectoral nerves. This procedure targets the right breast in the study to reduce postoperative pain and is compared to local anesthetic infiltration.

  • ProcedureLocal Anesthetic Infiltration

    Local anesthetic infiltration involves the intraoperative administration of 10 mL of 0.5% bupivacaine under direct visualization into the pectoralis major muscle prior to muscle transection. This procedure targets the left breast in the study for pain management and is compared to the PECS I block.

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Intensity

    The level of postoperative pain in each breast region (right vs. left) measured using the Numeric Rating Scale (NRS). Pain scores will be recorded at specific intervals: every 30 minutes for the first 2 hours, every 2 hours from 2 to 6 hours, at the 24th hour, on the 5th postoperative day, and at the 3rd month. The primary focus is the pain intensity within the first 6 hours postoperatively.

    Time frame: Up to 6 hours post-surgery.

Secondary outcomes

  1. Opioid Consumption

    Total tramadol consumption recorded within the first 6 hours and the first 24 hours postoperatively. This includes the amount administered via patient-controlled analgesia (PCA) and any additional doses required.

    Time frame: Up to 24 hours post-surgery.

  2. Opioid-Related Side Effects

    Incidence of opioid-related side effects such as nausea, vomiting, constipation, and respiratory depression. These will be monitored and recorded for each participant during the postoperative hospital stay

    Time frame: Up to 24 hours post-surgery

  3. Chronic Pain Assessment

    Presence of chronic pain in the breast region assessed using the Numeric Rating Scale (NRS) at the 3rd-month follow-up

    Time frame: At 3 months post-surgery

  4. Postoperative Complications

    Incidence of complications such as wound dehiscence, hematoma, infection, implant rupture, or sensory changes in the nipple. All complications will be recorded during routine follow-ups.

    Time frame: Up to 3 months post-surgery

07

Study locations

1 site
  • Yeditepe University Kozyatagi Hospital
    Istanbul, Atasehir 34752, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — The following specific individual participant data (IPD) will be shared: De-identified Participant Data: Demographic data (age, BMI, ASA classification). Pain scores measured using the Numeric Rating Scale (NRS) at predefined intervals. Postoperative opioid consumption (tramadol and morphine requirements). Incidence of postoperative complications (e.g., sensory changes, wound dehiscence). Data Dictionary: A comprehensive guide explaining the variables and coding used in the dataset to ensure accurate interpretation by other researchers. Exclusions: Personally identifiable information (e.g., names, contact information) will not be shared to maintain participant confidentiality. The data will be shared after the study is completed, analyzed, and the results are published in a peer-reviewed journal. Access will be granted only to researchers who provide a justified request and agree to the terms of a formal data-sharing agreement

Supporting information: Study protocol, Sap, Icf, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06719726
Lead sponsor
Yeditepe University Hospital
Responsible party
Mert Ersan (Asst. Prof., Yeditepe University Hospital) — Principal investigator
First posted
Dec 6, 2024
Start date
Oct 3, 2024
Primary completion
Jan 3, 2025
Completion
Feb 3, 2025
Last update
Jul 16, 2025

Study contacts

Mert Ersan, Asst.Prof.
principal investigator · Yeditepe University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion